International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUC
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAron Research Foundation Ets
About this trial
The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced/metastatic Urothelial Cancer.
Two supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.
Eligibility criteria
Qualifiers
Patients aged >18years
Histologically confirmed diagnosis of la/mUC of upper and/or lower urinary tract or histologically confirmed diagnosis of rare GU tumors.
Histologically or radiologically confirmed metastatic disease
Patients treated with first-line EV+P combination
Disqualifiers
Patients without histologically confirmed diagnosis of UC
Patients without histologically or radiologically confirmed la or mUC
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov